{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:57:23Z","timestamp":1791241043883,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13989-x","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:55:33Z","timestamp":1783673733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HBsAg seroreversion after pegylated interferon alpha induced HBsAg seroclearance in patients with chronic hepatitis B: a real-world cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Wencong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangbing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiurong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"13989_CR1","unstructured":"Global hepatitis report 2024: action for access in low- and middle-income countries. Updated 9. April 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240091672. (Accessed 21 April, 2025)."},{"issue":"2","key":"13989_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol Aug. 2017;67(2):370\u201398.","journal-title":"J Hepatol Aug"},{"issue":"4","key":"13989_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology Apr. 2018;67(4):1560\u201399.","journal-title":"Hepatology Apr"},{"issue":"3","key":"13989_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","volume":"75","author":"MG Martinez","year":"2021","unstructured":"Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J Hepatol Sep. 2021;75(3):706\u201317.","journal-title":"J Hepatol Sep"},{"issue":"3","key":"13989_CR5","first-page":"100112","volume":"2","author":"CL Lai","year":"2020","unstructured":"Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed. JHEP Rep Jun. 2020;2(3):100112.","journal-title":"JHEP Rep Jun"},{"issue":"2","key":"13989_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/apt.15053","volume":"49","author":"MT Kuo","year":"2019","unstructured":"Kuo MT, Hu TH, Hung CH, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther Jan. 2019;49(2):218\u201328.","journal-title":"Aliment Pharmacol Ther Jan"},{"issue":"23","key":"13989_CR7","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"4","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med Dec. 2008;4(23):2442\u201355.","journal-title":"N Engl J Med Dec"},{"issue":"9865","key":"13989_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"9","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet Feb. 2013;9(9865):468\u201375.","journal-title":"Lancet Feb"},{"issue":"8","key":"13989_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut Aug. 2014;63(8):1325\u201332.","journal-title":"Gut Aug"},{"issue":"3","key":"13989_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol Nov. 2016;1(3):185\u201395.","journal-title":"Lancet Gastroenterol Hepatol Nov"},{"issue":"1","key":"13989_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13099-021-00421-9","volume":"12","author":"G Wang","year":"2021","unstructured":"Wang G, Guan J, Khan NU, et al. Potential capacity of interferon-alpha to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog Apr. 2021;12(1):22.","journal-title":"Gut Pathog Apr"},{"issue":"12","key":"13989_CR12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"16","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med Sep. 2004;16(12):1206\u201317.","journal-title":"N Engl J Med Sep"},{"issue":"26","key":"13989_CR13","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"30","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med Jun. 2005;30(26):2682\u201395.","journal-title":"N Engl J Med Jun"},{"key":"13989_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1471-2334-11-165","volume":"9","author":"WC Li","year":"2011","unstructured":"Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis Jun. 2011;9:11:165.","journal-title":"BMC Infect Dis Jun"},{"issue":"3","key":"13989_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"M Bourliere","year":"2017","unstructured":"Bourliere M, Rabiega P, Ganne-Carrie N, et al. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol Mar. 2017;2(3):177\u201388.","journal-title":"Lancet Gastroenterol Hepatol Mar"},{"issue":"7","key":"13989_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jvh.13283","volume":"27","author":"MA Fonseca","year":"2020","unstructured":"Fonseca MA, Ling JZJ, Al-Siyabi O, Co-Tanko V, Chan E, Lim SG. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis. J Viral Hepat Jul. 2020;27(7):650\u201362.","journal-title":"J Viral Hepat Jul"},{"issue":"2","key":"13989_CR17","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","volume":"20","author":"SG Lim","year":"2022","unstructured":"Lim SG, Yang WL, Ngu JH, et al. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol Feb. 2022;20(2):e228\u201350.","journal-title":"Clin Gastroenterol Hepatol Feb"},{"issue":"1","key":"13989_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","volume":"150","author":"P Marcellin","year":"2016","unstructured":"Marcellin P, Ahn SH, Ma X, et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology Jan. 2016;150(1):134\u2013e14410.","journal-title":"Gastroenterology Jan"},{"issue":"5","key":"13989_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/ijerph13070730","volume":"21","author":"J Zhou","year":"2016","unstructured":"Zhou J, Wu X, Wei W, You H, Jia J, Kong Y. A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B. Int J Environ Res Public Health Jul. 2016;21(5):730.","journal-title":"Int J Environ Res Public Health Jul"},{"issue":"17","key":"13989_CR20","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"1","author":"LSY Tang","year":"2018","unstructured":"Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA May. 2018;1(17):1802\u201313.","journal-title":"JAMA May"},{"issue":"7","key":"13989_CR21","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/liv.14801","volume":"41","author":"CQ Pan","year":"2021","unstructured":"Pan CQ, Li MH, Yi W, et al. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver Int Jul. 2021;41(7):1498\u2013508.","journal-title":"Liver Int Jul"},{"issue":"2","key":"13989_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","volume":"58","author":"R Thimme","year":"2013","unstructured":"Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol Feb. 2013;58(2):205\u20139.","journal-title":"J Hepatol Feb"},{"issue":"Suppl 1","key":"13989_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/liv.12403","volume":"34","author":"M Martinot-Peignoux","year":"2014","unstructured":"Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int Feb. 2014;34(Suppl 1):97\u2013107.","journal-title":"Liver Int Feb"},{"issue":"7","key":"13989_CR24","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/infdis\/jiy272","volume":"24","author":"IC Lee","year":"2018","unstructured":"Lee IC, Yang SS, Lee CJ, et al. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. J Infect Dis Aug. 2018;24(7):1075\u201384.","journal-title":"J Infect Dis Aug"},{"issue":"1","key":"13989_CR25","doi-asserted-by":"publisher","first-page":"13873","DOI":"10.1038\/s41598-025-86555-1","volume":"22","author":"L Han","year":"2025","unstructured":"Han L, Wang Z, Kang L, et al. Predicting relapse after achieving a functional cure for chronic hepatitis B (CHB) using baseline HBsAg and end-of-treatment HBsAb levels. Sci Rep Apr. 2025;22(1):13873.","journal-title":"Sci Rep Apr"},{"issue":"18","key":"13989_CR26","doi-asserted-by":"publisher","first-page":"e163175","DOI":"10.1172\/JCI163175","volume":"15","author":"MG Ghany","year":"2022","unstructured":"Ghany MG, Lok AS. Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA. J Clin Invest Sep. 2022;15(18):e163175.","journal-title":"J Clin Invest Sep"},{"issue":"3","key":"13989_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/cmi.2015.25","volume":"12","author":"X Xu","year":"2015","unstructured":"Xu X, Shang Q, Chen X, et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol May. 2015;12(3):309\u201316.","journal-title":"Cell Mol Immunol May"},{"issue":"1","key":"13989_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12985-024-02522-8","volume":"3","author":"W Zhang","year":"2024","unstructured":"Zhang W, Chen J, Sun W, et al. The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment. Virol J Oct. 2024;3(1):243.","journal-title":"Virol J Oct"},{"issue":"Suppl 1","key":"13989_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jvh.13151","volume":"26","author":"MH Li","year":"2019","unstructured":"Li MH, Yi W, Zhang L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat Jul. 2019;26(Suppl 1):32\u201341.","journal-title":"J Viral Hepat Jul"},{"issue":"2","key":"13989_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cgh.2019.04.020","volume":"18","author":"Y Wu","year":"2020","unstructured":"Wu Y, Liu Y, Lu J, et al. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance. Clin Gastroenterol Hepatol Feb. 2020;18(2):514\u20136. e2.","journal-title":"Clin Gastroenterol Hepatol Feb"},{"issue":"10","key":"13989_CR31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jvh.13734","volume":"29","author":"N Gao","year":"2022","unstructured":"Gao N, Yu H, Zhang J, et al. Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy. J Viral Hepat Oct. 2022;29(10):899\u2013907.","journal-title":"J Viral Hepat Oct"},{"key":"13989_CR32","doi-asserted-by":"publisher","first-page":"1120300","DOI":"10.3389\/fcimb.2023.1120300","volume":"13","author":"Y Guo","year":"2023","unstructured":"Guo Y, Han J, Zhang Y, et al. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Front Cell Infect Microbiol. 2023;13:1120300.","journal-title":"Front Cell Infect Microbiol"},{"issue":"44","key":"13989_CR33","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.3748\/wjg.v30.i44.4725","volume":"28","author":"R Lu","year":"2024","unstructured":"Lu R, Zhang M, Liu ZH, et al. Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens. World J Gastroenterol Nov. 2024;28(44):4725\u201337.","journal-title":"World J Gastroenterol Nov"},{"issue":"2","key":"13989_CR34","doi-asserted-by":"publisher","first-page":"2259003","DOI":"10.1080\/22221751.2023.2259003","volume":"12","author":"S Yin","year":"2023","unstructured":"Yin S, Wan Y, Issa R, et al. The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment. Emerg Microbes Infect Dec. 2023;12(2):2259003.","journal-title":"Emerg Microbes Infect Dec"},{"key":"13989_CR35","doi-asserted-by":"publisher","first-page":"893512","DOI":"10.3389\/fimmu.2022.893512","volume":"13","author":"S Wu","year":"2022","unstructured":"Wu S, Yi W, Gao Y, et al. Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection. Front Immunol. 2022;13:893512.","journal-title":"Front Immunol"},{"issue":"3","key":"13989_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.virs.2022.03.001","volume":"37","author":"M Li","year":"2022","unstructured":"Li M, Sun F, Bi X, et al. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virol Sin Jun. 2022;37(3):390\u20137.","journal-title":"Virol Sin Jun"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13989-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13989-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13989-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:45:50Z","timestamp":1791240350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13989-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13989"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13989-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Ethics Committee of Tongji Hospital, Huazhong University of Science and Technology (Approval No. TJ-IRB20220929) and was conducted in accordance with the Declaration of Helsinki. As part of the ethics review process, an application for waiver of informed consent was reviewed and approved by the Ethics Committee. Therefore, the requirement for informed consent to participate was waived for this study. The data were collected from existing medical records and were anonymized before analysis to protect patient privacy.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1774"}}